<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01754779</url>
  </required_header>
  <id_info>
    <org_study_id>032012-058</org_study_id>
    <secondary_id>R21DK097476-01</secondary_id>
    <nct_id>NCT01754779</nct_id>
  </id_info>
  <brief_title>Treatment for Calcium Phosphate Kidney Stone Disease</brief_title>
  <official_title>Pharmacological Therapy for Calcium Phosphate Urolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine in two studies whether citric acid or potassium citrate can
      reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will examine in two short-term placebo-controlled cross-over metabolic studies whether
      citric acid or potassium citrate can reduce calcium phosphate saturation in urine of CaP
      stone formers. The first study will be conducted in hypocitraturic CaP stone formers without
      hypercalciuria, and will compare the effects of potassium citrate, citric acid and placebo.

      The second study will be conducted in hypercalciuric CaP stone formers on a thiazide diuretic
      who require potassium supplementation, and will compare the effects of potassium chloride
      alone, potassium chloride + citric acid, and potassium citrate alone. Physicochemical assays
      will be applied in addition to computer-based stone risk prediction programs to assess risk
      of stone recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary calcium phosphate saturation</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Calcium Phosphate Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will undergo 3 phases, the order of which will be randomized by a simple randomization scheme. The 3 phases will be Placebo, Citric Acid, and Potassium Citrate. Each phase will be 1 week in duration, during which subjects will take assigned study medications. A 1-week washout period is imposed between phases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each hypercalciuric CaP stone former will undergo 3 phases, the order of which will be randomized by a simple randomization scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for both aims.</description>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citric Acid</intervention_name>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium Citrate</intervention_name>
    <arm_group_label>Calcium Phosphate stone formers without hypercalciuria</arm_group_label>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide</intervention_name>
    <description>Aim 2</description>
    <arm_group_label>Calcium Phosphate stone formers with hypercalciuria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Aim 1

          -  Hypocitraturic CaP stone formers

          -  urine citrate &lt;320mg/d

          -  elevated pH as 24-hr urine pH above 6.40

          -  &gt;21 years

        Aim 2

          -  Hypercalciuric CaP stone formers

          -  24hr urine calcium &gt;250mg/d in women and &gt;300mg/d in men prior to indapamide use

          -  high pH as &gt;6.40 in the absence of urinary tract infection

          -  &gt;21 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naim M Maalouf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Heard-Sakhaee, RN</last_name>
    <phone>214-648-4893</phone>
    <email>ann.heard-sakhaee@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8885</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naim M Maalouf, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2012</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Naim Maalouf</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>calcium phosphate</keyword>
  <keyword>urolithiasis</keyword>
  <keyword>kidney stones</keyword>
  <keyword>hypercalciuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

